Entrada Therapeutics Inc
Research Entrada Therapeutics Inc (TRDA) on Bullrun: market cap USD 296.70M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRDA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 296.70M
- Financial periodQ2 2026
- RevenueUSD 898.00K
- Net income-USD 42.76M
- Free cash flow-USD 32.47M
Valuation Snapshot
latest market cap is USD 296.70M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 25.42M | -USD 143.75M | -USD 129.55M | n/a | -3.47 | USD 90.39M | USD 50.93M | USD 306.13M |
| FY2024 | USD 210.78M | USD 65.63M | -USD 44.72M | n/a | 1.68 | USD 101.21M | USD 59.21M | USD 428.68M |
| FY2023 | USD 129.01M | -USD 6.69M | USD 134.19M | n/a | -0.2 | USD 67.60M | USD 68.23M | USD 242.36M |
| FY2022 | n/a | -USD 94.62M | -USD 96.67M | n/a | -3.02 | USD 45.16M | USD 29.92M | USD 212.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 296.70M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 393.56M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 649.66M | 9.1 | n/a | n/a |
| 2023 | 2023-12-29 | USD 503.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 424.61M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 534.56M | n/a | n/a | n/a |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Entrada Therapeutics Inc's market cap?
Entrada Therapeutics Inc's market capitalization is USD 296.70M.
What does Entrada Therapeutics Inc do?
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670.